Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 20/20 | 1.00 |
| ▸ | CSF1R | P07333 | 20/20 | 1.00 |
| ▸ | NTRK2 | Q16620 | 20/20 | 1.00 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29774381 | 1.00 | NTRK1 (1.00) | NTRK1CSF1RNTRK2NTRK3 | |
| SCHEMBL16763035 | 0.94 | NTRK1 (1.00) | NTRK1CSF1RNTRK2NTRK3 | |
| SCHEMBL29774365 | 0.94 | NTRK1 (1.00) | NTRK1CSF1RNTRK2NTRK3 | |
| SCHEMBL16762913 | 0.92 | NTRK1 (1.00) | NTRK1CSF1RNTRK2NTRK3 | |
| SCHEMBL29774376 | 0.92 | NTRK1 (1.00) | NTRK1CSF1RNTRK2NTRK3 | |
| SCHEMBL29774452 | 0.91 | NTRK1 (1.00) | NTRK1CSF1RNTRK2NTRK3 | |
| SCHEMBL29774423 | 0.91 | CSF1R (1.00) | NTRK1CSF1RNTRK2NTRK3 | |
| SCHEMBL16763173 | 0.91 | CSF1R (1.00) | NTRK1CSF1RNTRK2NTRK3 | |
| SCHEMBL16763058 | 0.91 | NTRK1 (1.00) | NTRK1CSF1RNTRK2NTRK3 | |
| Gz-389988 SCHEMBL29774374 | 0.90 | CSF1R (1.00) | NTRK1CSF1RNTRK2NTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288595-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | GENZYME CORP (US) | 2025-09-18 | — | — | US | disclosed |
| US-12318392-B2 | Tropomyosin-related kinase (trk) inhibitors | GENZYME CORPORATION (US) | 2025-06-03 | — | — | US | disclosed |
| US-20240189322-A1 | TROPOMYOSIN-RELATED KINASE (trk) INHIBITORS | GENZYME CORPORATION | 2024-06-13 | — | — | US | disclosed |
| US-11878024-B2 | Tropomyosin-related kinase (Trk) inhibitors | GENZYME CORPORATION (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230080874-A1 | TROPOMYOSIN-RELATED KINASE (trk) INHIBITORS | GENZYME CORPORATION | 2023-03-16 | — | — | US | disclosed |
| US-11406644-B2 | Tropomyosin-related kinase (TRK) inhibitors | GENZYME CORPORATION (US) | 2022-08-09 | — | — | US | disclosed |
| EP-3848368-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | Genzyme Corporation (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210169894-A1 | Tropomyosin-Related Kinase (TRK) Inhibitors | GENZYME CORPORATION | 2021-06-10 | — | — | US | disclosed |
| US-20210169894-A1 | Tropomyosin-Related Kinase (TRK) Inhibitors | GENZYME CORPORATION | 2021-06-10 | — | — | US | disclosed |
| EP-3080108-B1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | GENZYME CORP (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20150274725-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | GENZYME CORPORATION | 2015-10-01 | — | — | US | disclosed |
| US-20150191466-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | GENZYME CORPORATION | 2015-07-09 | — | — | US | disclosed |
| US-20150191466-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | GENZYME CORPORATION | 2015-07-09 | — | — | US | disclosed |
| US-20150191466-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | GENZYME CORPORATION | 2015-07-09 | — | — | US | disclosed |
| US-9067914-B1 | Tropomyosin-related kinase (TRK) inhibitors | GENZYME CORPORATION (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067914-B1 | Tropomyosin-related kinase (TRK) inhibitors | GENZYME CORPORATION (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067914-B1 | Tropomyosin-related kinase (TRK) inhibitors | GENZYME CORPORATION (US) | 2015-06-30 | — | — | US | disclosed |
| US-20150158847-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | GENZYME CORPORATION | 2015-06-11 | — | — | US | disclosed |
| US-20150158847-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | GENZYME CORPORATION | 2015-06-11 | — | — | US | disclosed |
| US-20150158847-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | GENZYME CORPORATION | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158847-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | NTRK1, NGF, NTRK2 | NTRK1 1/4885CSF1R 4/4885NTRK2 3/4885 |
| US-20210169894-A1 | Tropomyosin-Related Kinase (TRK) Inhibitors | NTRK1, NGF, NTRK2 | NTRK1 1/4885CSF1R 4/4885NTRK2 3/4885 |
| US-12318392-B2 | Tropomyosin-related kinase (trk) inhibitors | NTRK1, NGF, NTRK2 | NTRK1 1/4885CSF1R 4/4885NTRK2 3/4885 |
| US-20150191466-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | NTRK1, NGF, NTRK2 | NTRK1 1/4885CSF1R 4/4885NTRK2 3/4885 |
| US-11406644-B2 | Tropomyosin-related kinase (TRK) inhibitors | NTRK1, NGF, NTRK2 | NTRK1 1/4885CSF1R 4/4885NTRK2 3/4885 |
| US-20230080874-A1 | TROPOMYOSIN-RELATED KINASE (trk) INHIBITORS | NTRK1, NGF, NTRK2 | NTRK1 1/4885CSF1R 4/4885NTRK2 3/4885 |
| US-20240189322-A1 | TROPOMYOSIN-RELATED KINASE (trk) INHIBITORS | NTRK1, NGF, NTRK2 | NTRK1 1/4885CSF1R 4/4885NTRK2 3/4885 |
| US-11878024-B2 | Tropomyosin-related kinase (Trk) inhibitors | NTRK1, NGF, NTRK2 | NTRK1 1/4885CSF1R 4/4885NTRK2 3/4885 |
| US-20150274725-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | NTRK1, NGF, NTRK2 | NTRK1 1/4885CSF1R 4/4885NTRK2 3/4885 |
| US-20250288595-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | NTRK1, NGF, NTRK2 | NTRK1 1/4885CSF1R 4/4885NTRK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.